{
    "nctId": "NCT02217033",
    "briefTitle": "Effects of 'R' (Electro-kinetic Beverage) on Insomnia, Fatigue, and Depression in Breast Cancer Patients Having Adjuvant Chemo",
    "officialTitle": "A Pilot Study Evaluating the Effect of 'R' (Electro-Kinetically Altered Beverage) on Insomnia, Fatigue and Depression in Breast Cancer Patients Receiving Adjuvant Chemotherapy",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 16,
    "primaryOutcomeMeasure": "The effects of consuming \"R\" on quality of life in the areas of insomnia in breast cancer patients receiving multi-cycle adjuvant chemotherapy",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female, non-smokers \u2265 18 years of age\n* Histologically or cytologically confirmed diagnosis of Stage I or II adenocarcinoma of the breast and a candidate for adjuvant chemotherapy\n* Scheduled to receive 4 cycles of adjuvant Taxotere and Cytoxan chemotherapy (TC): docetaxel 75 mg/m2 and cyclophosphamide 600 mg/m2 administered intravenously on Day 1 of each 21-day cycle\n* Eastern Cooperative Oncology Group Status (ECOG) performance status of \u2264 1\n* No prior treatment for breast cancer other than surgery\n* Adequate baseline organ function as evidenced by:\n\n  * Hemoglobin \u2265 9 g/dL\n  * Absolute neutrophil count \u2265 1.5 x 109 cells/mm3\n  * Platelet count \u2265 100,000 cells/mm3\n  * Serum creatinine \u2264 1.5 x upper limit of normal (ULN)\n  * Alkaline phosphatase \u2264 1.5 x ULN\n* No history of other malignancies within the last 5 years, except for carcinoma in situ of the cervix, or basal cell carcinoma or squamous cell carcinoma of the skin that have been previously treated with curative intent\n* Women of childbearing potential who commit to using two forms of highly effective non-hormonal contraception either by the subject and/or partner during the study\n* Negative urine pregnancy test at screening\n* Negative urine drug screen (UDS) for drugs of abuse including cotinine (nicotine) at screening\n* Subjects must be capable of understanding the purpose and risks of the study and provide written, voluntary informed consent\n\nExclusion Criteria:\n\n* Preexisting diagnosed psychiatric disorder as defined by The Diagnostic and Statistical Manual (DSM) of Mental Disorders (published by the American Psychiatric Association). Subjects with a diagnosis of depression will be allowed to enter into study as long as they have been treated with medication for \u2265 6 months and/or depression is considered to be well controlled\n* Pregnant or lactating\n* Diabetes\n* Concomitant use of any sleeping agents during the course of the study (Anti- anxiety medications will be allowed)\n* Steroid therapy other than the standard prescribed therapy of either of the following during the course of the study:\n\n  * Dexamethasone 4-12 mg IV on Day 1 of any cycle\n  * Dexamethasone 4-12 mg PO on Day 2 and Day 3 of any cycle\n* Anti-estrogen therapy other than the standard prescribed therapy of one of the following:\n\n  * Tamoxifen/Nolvadex 20 mg PO daily\n  * Anastrazole/Arimidex 1 mg PO daily\n  * Letrozole/Femara 2.5 mg PO daily\n  * Exemestane/Aromasin 25 mg PO daily\n* Use of any other antiemetic regimen other than the following (with the exception of PO antiemetics):\n\n  * Emend /Aprepitant150 mg IV on Day 1 of any cycle\n  * Aloxi/Palonosetron 0.25 mg IV on Day 1 of any cycle\n  * Dexamethasone 8 mg IV on Day 1 of any cycle\n  * Dexamethasone 8 mg PO on Day 2 and Day 3 of any cycle\n  * Zofran/Ondansetron 12 mg IV on Day 1 of any cycle\n  * Kytrile/Granisetron 1-2 mg IV on Day 1 of any cycle\n* Therapy with any immunomodulatory or immunosuppressive drugs within 6 months prior to enrollment\n* Known history of positive viral serology test for Human Immunodeficiency Virus (HIV-1), HBsAG and Hepatitis C antibody\n* Any change in the initially prescribed chemotherapy\n* Use of herbal remedies, dietary supplements or mega-vitamins, with the exception of a multi-vitamin\n* Investigator deems the subject to be unable or unwilling to comply with the requirements of the protocol",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}